Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

@article{Rybak2009TherapeuticMO,
  title={Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.},
  author={Michael Rybak and Ben M. Lomaestro and John C. Rotschafer and Robert C. Moellering and William A. Craig and Marianne Billeter and Joseph R. Dalovisio and Donald P Levine},
  journal={American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists},
  year={2009},
  volume={66 1},
  pages={
          82-98
        }
}
  • M. RybakB. Lomaestro D. Levine
  • Published 2009
  • Medicine, Biology
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus . It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive 

Tables from this paper

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.

  • M. RybakB. Lomaestro D. Levine
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
A literature review of existing evidence regarding vancomycin dosing and monitoring of serum concentrations, in addition to patient outcomes combined with expert opinion regarding the drug's pharmacokinetic, pharmacodynamic, and safety record, resulted in new recommendations for targeting and adjustment of vancomYcin therapy.

Clinical Guideline Highlights for the Hospitalist: Therapeutic Monitoring of Vancomycin.

Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections is reviewed by the American Society of Health-System Pharmacists, IDSA, PIDS, SIDP, and the Society of Infectious Diseases Pharmacists.

Optimizing the Clinical Use of Vancomycin

This review analyzes the new available information about vancomycin published in recent years regarding pharmacokinetics and pharmacodynamics, serum concentration monitoring, and optimal vancomYcin dosing in special situations (obese people, burn patients, renal replacement therapy, among others).

Vancomycin-Associated Nephrotoxicity and the Use of Higher Trough Concentrations in Infants and Children

Wide-spread use over the past 50 years eventually has led to reduced sensitivity to vancomycin and the development of resistance.

Therapeutic Monitoring of Vancomycin in Adults

The area under the concentration‐time curve (AUC):minimum inhibitory concentration (MIC) ratio is the most useful pharmacodynamic parameter to predict vancomycin effectiveness and a target ratio of 400 or greater to eradicate S. aureus infections is suggested.

Pharmacist and physician insight of vancomycin therapeutic drug-monitoring changes

The updated vancomycin guideline for treatment of serious methicillin-resistant Staphylococcus aureus infections prompted institutions to convert from trough to area-under-the-curve monitoring, and physician perception of the transition and that of pharmacists believed safety would be increased without efficacy changes.

Understanding vancomycin levels.

Low vancomycin levels are used to optimize dosing to help prevent bacterial resistance, improve patient outcomes, and avoid drug toxicity in clinical practice.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

  • Catherine LiuA. Bayer H. Chambers
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
These guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system infections.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

  • Catherine LiuA. Bayer H. Chambers
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
These guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system infections.

Retrospective analysis of vancomycin treatment outcomes in Chinese paediatric patients with suspected Gram‐positive infection

The relationships between vancomycin trough concentration and treatment outcomes in Chinese paediatric patients with suspected Gram‐positive infections are evaluated and baseline characteristics that may affect treatment failure associated with vancomYcin use are identified.
...

References

SHOWING 1-10 OF 166 REFERENCES

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists.

The Review is a welcome and up-to-date consensus statement on the use of vancomycin and it is hoped the new TG (Version 14) will be used as a springboard for Australasian clinical research into this area.

The pharmacokinetic and pharmacodynamic properties of vancomycin.

  • M. Rybak
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
The pharmacokinetic and pharmacodynamic data related to vancomycin are reviewed and such clinical issues as toxicities and serum concentration monitoring are discussed.

Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases.

A potent bactericidal antibiotic that can be administered to patients in large doses, and to which staphylococci do not quickly become resistant, has been lacking.

Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence.

  • S. Deresinski
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
Although no clinical trials suggest superiority of vancomycin over any comparator, some have provided evidence of its inferiority, strong consideration should be given to the use of alternative agents in the treatment of serious S. aureus infections.

A prospective study of adverse reactions associated with vancomycin therapy.

It is concluded that vancomycin, administered appropriately, constitutes safe, effective therapy for infections caused by susceptible bacteria.

Comparative Clinical Effectiveness and Toxicity of Vancomycin, Ristocetin, and Kanamycin

It was possible to alternate the use of ristocetin, vancomycin, and kanamycin in a group of seriously ill patients because the three drugs were discovered within such a short time of each other that no one had an opportunity to be established as "the drug of choice" in severe staphylococcic infections.

Vancomycin: a history.

  • D. Levine
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
The findings of future studies may result in a return to measuring levels of vancomycin in serum, to assure a successful therapeutic outcome, and to rekindled interest in the best way to administer the antibiotic.

The role of vancomycin in the treatment paradigm.

  • D. Stevens
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
The efficacy of vancomycin has been questioned because of van comycin's increasing minimum inhibitory concentrations among staphylococci, poor tissue penetration, and apparently slower bacterial killing than previously was recognized.

Monitoring Vancomycin Therapy

The relationship between serum concentrations of vancomycin and the occurrence of ototoxicity or nephrotoxicity has not been well established and it seems preferable to individualize vancomYcin therapy based on serum concentration data.

Vancomycin-Induced Neutropenia during Treatment of Osteomyelitis in an Outpatient

A case of vancomycin-associated neutropenia occurring during long-term outpatient therapy with vancomYcin is described, and an immunologic mechanism has been proposed but a clear understanding is lacking.
...